DIC: Which laboratory tests are most useful

Blood Reviews

Volumn 25, Issue 1, 2011, Pages 33-37

  Levi, Marcel ^a   Meijers, Joost C ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

Coagulation factors; Coagulation inhibitors; Disseminated intravascular coagulation; Fibrin degradation products; Platelets; Scoring systems

Indexed keywords

ANTITHROMBIN III; BLOOD CLOTTING FACTOR; BLOOD CLOTTING INHIBITOR; FIBRIN; FIBRINOGEN; PROTEIN C; THROMBOMODULIN;

ALGORITHM; ARTICLE; BLOOD CLOTTING DISORDER; BLOOD CLOTTING TEST; DIAGNOSTIC ACCURACY; DISSEMINATED INTRAVASCULAR CLOTTING; FIBRINOLYSIS; HUMAN; LABORATORY TEST; PATHOGENESIS; PRIORITY JOURNAL; PROTHROMBIN TIME; SCORING SYSTEM; THROMBOCYTE COUNT; THROMBOCYTOPENIA; THROMBOELASTOGRAPHY; THROMBOPLASTIN TIME;

BIOLOGICAL MARKERS; BLOOD COAGULATION TESTS; DISSEMINATED INTRAVASCULAR COAGULATION; FIBRIN FIBRINOGEN DEGRADATION PRODUCTS; HUMANS;

EID: 78649906616     PISSN: 0268960X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.blre.2010.09.002     Document Type: Article

References (77)

1. Levi M. Disseminated intravascular coagulation: a disease-specific approach. Semin Thromb Hemost 2010, 36(4):363-365.
2. Levi M., ten Cate H. Disseminated intravascular coagulation. N Engl J Med 1999, 341(8):586-592.
3. Levi M. Disseminated intravascular coagulation. Crit Care Med 2007, 35:2191-2195.
4. Favaloro E.J. Laboratory testing in disseminated intravascular coagulation. Semin Thromb Hemost 2010, 36(4):458-467.
5. Levi M., Toh C.H., Thachil J., Watson H.G. Guidelines for the diagnosis and management of disseminated intravascular coagulation. British Committee for Standards in Haematology. Br J Haematol 2009, 145(1):24-33.
6. Vanderschueren S., De Weerdt A., Malbrain M., Vankersschaever D., Frans E., Wilmer A., et al. Thrombocytopenia and prognosis in intensive care. Crit Care Med 2000, 28(6):1871-1876.
7. Baughman R.P., Lower E.E., Flessa H.C., Tollerud D.J. Thrombocytopenia in the intensive care unit. Chest 1993, 104(4):1243-1247.
8. Strauss R., Wehler M., Mehler K., Kreutzer D., Koebnick C., Hahn E.G. Thrombocytopenia in patients in the medical intensive care unit: bleeding prevalence, transfusion requirements, and outcome. Crit Care Med 2002, 30(8):1765-1771.
9. Stephan F., Hollande J., Richard O., Cheffi A., Maier-Redelsperger M., Flahault A. Thrombocytopenia in a surgical ICU. Chest 1999, 115(5):1363-1370.
10. Hanes S.D., Quarles D.A., Boucher B.A. Incidence and risk factors of thrombocytopenia in critically ill trauma patients. Ann Pharmacother 1997, 31(3):285-289.
11. Levi M.M., Eerenberg E., Lowenberg E., Kamphuisen P.W. Bleeding in patients using new anticoagulants or antiplatelet agents: risk factors and management. Neth J Med 2010, 68(2):68-76.
12. Oppenheim-Eden A., Glantz L., Eidelman L.A., Sprung C.L. Spontaneous intracerebral hemorrhage in critically ill patients: incidence over six years and associated factors. Intensive Care Med 1999, 25(1):63-67.
13. Akca S., Haji Michael P., de Medonca A., Suter P.M., Levi M., Vincent J.L. The time course of platelet counts in critically ill patients. Crit Care Med 2002, 30:753-756.
14. Levi M., Opal S.M. Coagulation abnormalities in critically ill patients. Crit Care 2006, 10(4):222-228.
15. Bick R.L. Disseminated intravascular coagulation: objective clinical and laboratory diagnosis, treatment, and assessment of therapeutic response. Semin Thromb Hemost 1996, 22(1):69-88.
16. Chakraverty R., Davidson S., Peggs K., Stross P., Garrard C., Littlewood T.J. The incidence and cause of coagulopathies in an intensive care population. Br J Haematol 1996, 93(2):460-463.
17. MacLeod J.B., Lynn M., McKenney M.G., Cohn S.M., Murtha M. Early coagulopathy predicts mortality in trauma. J Trauma 2003, 55(1):39-44.
18. Greaves M., Preston F.E. Approach to the bleeding patient. Hemostasis and thrombosis. Basic principles and clinical practice 2001, 1031-1043. Lippingcott William&Wilkins, Philadelphia. 4th edition. R.W. Colman, J. Hirsh, V.J. Marder, A.W. Clowes, J.N. George (Eds.).
19. Edmunds L.H. Hemostatic problems in surgical patients. Hemostasis and thrombosis. Basic principles and clinical practice 2001, 1031-1043. Lippingcott William&Wilkins, Philadelphia. 4th edition. R.W. Colman, J. Hirsh, V.J. Marder, A.W. Clowes, J.N. George (Eds.).
20. Kitchen S., Preston F.E. Standardization of prothrombin time for laboratory control of oral anticoagulant therapy. Semin Thromb Hemost 1999, 25(1):17-25.
21. Lowenberg E.C., Meijers J.C., Levi M. Platelet-vessel wall interaction in health and disease. Neth J Med 2010, 68(6):242-251.
22. Levi M., de Jonge E., Meijers J. The diagnosis of disseminated intravascular coagulation. Blood Rev 2002, 16(4):217-223.
23. Bakhtiari K., Meijers J.C., de Jonge E., Levi M. Prospective validation of the international society of thrombosis and maemostasis scoring system for disseminated intravascular coagulation. Crit Care Med 2004, 32:2416-2421.
24. Dempfle C.E. The use of soluble fibrin in evaluating the acute and chronic hypercoagulable state. Thromb Haemost 1999, 82(2):673-683.
25. Bredbacka S., Blomback M., Wiman B., Pelzer H. Laboratory methods for detecting disseminated intravascular coagulation (DIC): new aspects. Acta Anaesthesiol Scand 1993, 37(2):125-130.
26. McCarron B.I., Marder V.J., Kanouse J.J., Francis C.W. A soluble fibrin standard: comparable dose-response with immunologic and functional assays. Thromb Haemost 1999, 82(1):145-148.
27. Shorr A.F., Thomas S.J., Alkins S.A., Fitzpatrick T.M., Ling G.S. D-dimer correlates with proinflammatory cytokine levels and outcomes in critically ill patients. Chest 2002, 121(4):1262-1268.
28. Owings J.T., Gosselin R.C., Anderson J.T., Battistella F.D., Bagley M., Larkin E.C. Practical utility of the D-dimer assay for excluding thromboembolism in severely injured trauma patients. J Trauma 2001, 51(3):425-429.
29. Bernard G.R., Vincent J.L., Laterre P.F., LaRosa S.P., Dhainaut J.F., Lopez-Rodriguez A., et al. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 2001, 344(10):699-709.
30. Boisclair M.D., Ireland H., Lane D.A. Assessment of hypercoagulable states by measurement of activation fragments and peptides. Blood Rev 1990, 4(1):25-40.
31. Levi M. The coagulant response in sepsis. Clin Chest Med 2008, 29(4):627-642. viii.
32. Levi M. The diagnosis of disseminated intravascular coagulation made easy. Neth J Med 2007, 65(10):366-367.
33. Levi M., van der Poll T. The role of natural anticoagulants in the pathogenesis and management of systemic activation of coagulation and inflammation in critically ill patients. Semin Thromb Hemost 2008, 34(5):459-468.
34. Gando S., Nanzaki S., Sasaki S., Kemmotsu O. Significant correlations between tissue factor and thrombin markers in trauma and septic patients with disseminated intravascular coagulation. Thromb Haemost 1998, 79(6):1111-1115.
35. Seitz R., Wolf M., Egbring R., Havemann K. The disturbance of hemostasis in septic shock: role of neutrophil elastase and thrombin, effects of antithrombin III and plasma substitution. Eur J Haematol 1989, 43(1):22-28.
36. Opal S.M., Kessler C.M., Roemisch J., Knaub S. Antithrombin, heparin, and heparan sulfate. Crit Care Med 2002, 30(5 Suppl):S325-S331.
37. Fijnvandraat K., Derkx B., Peters M., Bijlmer R., Sturk A., Prins M.H., et al. Coagulation activation and tissue necrosis in meningococcal septic shock: severely reduced protein C levels predict a high mortality. Thromb Haemost 1995, 73(1):15-20.
38. Esmon C.T. New mechanisms for vascular control of inflammation mediated by natural anticoagulant proteins. J Exp Med 2002, 196(5):561-564.
39. Zushi M., Gomi K., Yamamoto S., Maruyama I., Hayashi T., Suzuki K. The last three consecutive epidermal growth factor-like structures of human thrombomodulin comprise the minimum functional domain for protein C-activating cofactor activity and anticoagulant activity. J Biol Chem 1989, 264(18):10351-10353.
40. Bajzar L., Morser J., Nesheim M. TAFI, or plasma procarboxypeptidase B, couples the coagulation and fibrinolytic cascades through the thrombin-thrombomodulin complex. J Biol Chem 1996, 271(28):16603-16608.
41. Taylor F.B., Peer G.T., Lockhart M.S., Ferrell G., Esmon C.T. Endothelial cell protein C receptor plays an important role in protein C activation in vivo. Blood 2001, 97(6):1685-1688.
42. Anas A., Wiersinga W.J., de Vos A.F., van der Poll T. Recent insights into the pathogenesis of bacterial sepsis. Neth J Med 2010, 68:157-162.
43. Faust SN, Levin M, Harrison OB, Goldin RD, Lockhart MS, Kondaveeti S, et al. Dysfunction of endothelial protein C activation in severe meningococcal sepsis. N Engl J Med 2001 Aug 9;345 (6 ):408-16345(6):408-416.
44. Garcia de Frutos P., Alim R.I., Hardig Y., Zoller B., Dahlback B. Differential regulation of alpha and beta chains of C4b-binding protein during acute-phase response resulting in stable plasma levels of free anticoagulant protein S. Blood 1994, 84(3):815-822.
45. Taylor F., Chang A., Ferrell G., Mather T., Catlett R., Blick K., et al. C4b-binding protein exacerbates the host response to Escherichia coli. Blood 1991, 78(2):357-363.
46. Broze G.J., Girard T.J., Novotny W.F. Regulation of coagulation by a multivalent Kunitz-type inhibitor. Biochemistry 1990, 29(33):7539-7546.
47. Novotny W.F., Brown S.G., Miletich J.P., Rader D.J., Broze G.J. Plasma antigen levels of the lipoprotein-associated coagulation inhibitor in patient samples. Blood 1991, 78(2):387-393.
48. Gando S., Kameue T., Morimoto Y., Matsuda M., Hayakawa M., Kemmotsu O. Tissue factor production not balanced by tissue factor pathway inhibitor in sepsis promotes poor prognosis. Crit Care Med 2002, 30(8):1729-1734.
49. Levi M. The imbalance between tissue factor and tissue factor pathway inhibitor in sepsis. Crit Care Med 2002, 30(8):1914-1915.
50. van der Poll T., Levi M., Buller H.R., van Deventer S., de Boer J., Hack C.E., et al. Fibrinolytic response to tumor necrosis factor in healthy subjects. J Exp Med 1991, 174(3):729-732.
51. Biemond B.J., Levi M., ten Cate H., van der Poll T., Buller H.R., Hack C.E., et al. Plasminogen activator and plasminogen activator inhibitor I release during experimental endotoxaemia in chimpanzees: effect of interventions in the cytokine and coagulation cascades. Clin Sci (Colch ) 1995, 88(5):587-594.
52. Levi M., ten Cate H., van der Poll T., van Deventer S. Pathogenesis of disseminated intravascular coagulation in sepsis. JAMA 1993, 270(8):975-979.
53. Harpel P.C. Alpha2-plasmin inhibitor and alpha2-macroglobulin-plasmin complexes in plasma. Quantitation by an enzyme-linked differential antibody immunosorbent assay. J Clin Invest 1981, 68(1):46-55.
54. Levi M., de Boer J., Roem D., ten Cate J.W., Hack C.E. Plasminogen activation in vivo upon intravenous infusion of DDAVP. Quantitative assessment of plasmin-alpha 2-antiplasmin complex with a novel monoclonal antibody based radioimmunoassay. Thromb Haemost 1992, 67(1):111-116.
55. Levi M., Roem D., Kamp A.M., De B.J., Hack C.E., ten C.J. Assessment of the relative contribution of different protease inhibitors to the inhibition of plasmin in vivo. Thromb Haemost 1993, 69(2):141-146.
56. Mesters R.M., Florke N., Ostermann H., Kienast J. Increase of plasminogen activator inhibitor levels predicts outcome of leukocytopenic patients with sepsis. Thromb Haemost 1996, 75(6):902-907.
57. Hermans P.W., Hibberd M.L., Booy R., Daramola O., Hazelzet J.A., de Groot R., et al. 4G/5G promoter polymorphism in the plasminogen-activator-inhibitor-1 gene and outcome of meningococcal disease. Meningococcal Research Group. Lancet 1999, 354(9178):556-560.
58. ten C.H., Bauer K.A., Levi M., Edgington T.S., Sublett R.D., Barzegar S., et al. The activation of factor X and prothrombin by recombinant factor VIIa in vivo is mediated by tissue factor. J Clin Invest 1993, 92(3):1207-1212.
59. Nossel H.L., Yudelman I., Canfield R.E., Butler V.P.J., Spanondis K., Wilner, et al. Measurement of fibrinopeptide A in human blood. J Clin Invest 1974, 54(1):43-53.
60. Dempfle C.E., Borggrefe M. Point of care coagulation tests in critically ill patients. Semin Thromb Hemost 2008, 34(5):445-450.
61. Johansson P.I., Stensballe J., Vindelov N., Perner A., Espersen K. Hypocoagulability, as evaluated by thrombelastography, at admission to the ICU is associated with increased 30-day mortality. Blood Coagul Fibrinolysis 2010, 21(2):168-174.
62. Park M.S., Martini W.Z., Dubick M.A., Salinas J., Butenas S., Kheirabadi B.S., et al. Thromboelastography as a better indicator of hypercoagulable state after injury than prothrombin time or activated partial thromboplastin time. J Trauma 2009, 67(2):266-275.
63. Collins P.W., Macchiavello L.I., Lewis S.J., Macartney N.J., Saayman A.G., Luddington R., et al. Global tests of haemostasis in critically ill patients with severe sepsis syndrome compared to controls. Br J Haematol 2006, 135(2):220-227.
64. Toh C.H., Samis J., Downey C., Walker J., Becker L., Brufatto N., et al. Biphasic transmittance waveform in the APTT coagulation assay is due to the formation of a Ca(++)-dependent complex of C-reactive protein with very-low-density lipoprotein and is a novel marker of impending disseminated intravascular coagulation. Blood 2002, 100(7):2522-2529.
65. Toh C.H. Transmittance waveform of routine coagulation tests is a sensitive and specific method for diagnosing non-overt disseminated intravascular coagulation. Blood Rev 2002, 16(Suppl 1):S11-S14.
66. Taylor F.B.J., Toh C.H., Hoots W.K., Wada H., Levi M. Towards definition, clinical and laboratory criteria, and a scoring system for disseminated intravascular coagulation. Thromb Haemost 2001, 86(5):1327-1330.
67. Wada H., Hatada T., Okamoto K., Uchiyama T., Kawasugi K., Mayumi T., et al. Modified non-overt DIC diagnostic criteria predict the early phase of overt-DIC. Am J Hematol 2010, 85(9):691-694.
68. Kim H.K., Hong K.H., Toh C.H. Application of the international normalized ratio in the scoring system for disseminated intravascular coagulation. J Thromb Haemost 2010, 8(5):1116-1118.
69. Horan JT, Francis CW. Fibrin degradation products, fibrin monomer and soluble fibrin in disseminated intravascular coagulation. Semin Thromb Hemost 2001 Dec;27 (6 ):657-6627(6):657-666.
70. Toh C.H., Hoots W.K. The scoring system of the Scientific and Standardisation Committee on Disseminated Intravascular Coagulation of the International Society on Thrombosis and Haemostasis: a five year overview. J Thromb Haemost 2007, 5604-5606.
71. Levi M. Disseminated intravascular coagulation in cancer patients. Best Pract Res Clin Haematol 2009, 22(1):129-136.
72. Thachil J., Toh C.H. Disseminated intravascular coagulation in obstetric disorders and its acute haematological management. Blood Rev 2009, 23(4):167-176.
73. Dhainaut J.F., Yan S.B., Joyce D.E., Pettila V., Basson B.R., Brandt J.T., et al. Treatment effects of drotrecogin alfa (activated) in patients with severe sepsis with or without overt disseminated intravascular coagulation. J Thromb Haemost 2004, 2:1924-1933.
74. Wada H., Gabazza E.C., Asakura H., Koike K., Okamoto K., Maruyama I., et al. Comparison of diagnostic criteria for disseminated intravascular coagulation (DIC): diagnostic criteria of the International Society of Thrombosis and Hemostasis and of the Japanese Ministry of Health and Welfare for overt DIC. Am J Hematol 2003, 74(1):17-22.
75. Levi M. Settling the score for disseminated intravascular coagulation. Crit Care Med 2005, 33(10):2417-2418.
76. Dhainaut J.F., Shorr A.F., Macias W.L., Kollef M.J., Levi M., Reinhart K., et al. Dynamic evolution of coagulopathy in the first day of severe sepsis: relationship with mortality and organ failure. Crit Care Med 2005, 33(2):341-348.
77. Kinasewitz G.T., Zein J.G., Lee G.L., Nazir S.R., Taylor F.B. Prognostic value of a simple evolving DIC score in patients with severe sepsis. Crit Care Med 2005, 33(10):2214-2221.